Form 4: Ligand Pharmaceuticals CLO Executes Stock Option Plan

Ligand Pharmaceuticals Chief Legal Officer Andrew Reardon exercised 5,000 stock options and sold the resulting shares under a Rule 10b5-1 trading plan.

Summary

• Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals, exercised 5,000 stock options at a strike price of $52.27.
• Following the exercise, the reporting person sold the 5,000 shares in multiple transactions on May 1, 2026.
• The sales were executed at weighted-average prices ranging from $227.45 to $234.02 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 24, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan and represents standard executive financial planning.

Positives

• The executive retains a significant beneficial ownership of 41,382 shares of common stock following the transactions.
• The transactions were pre-planned under a Rule 10b5-1 plan, indicating the sales were not based on immediate non-public information.

Negatives

• The transaction represents a divestment of 5,000 shares by a key member of the executive leadership team.

Risks

• Future share price volatility could impact the value of remaining holdings for the executive.
• Reliance on Rule 10b5-1 plans is standard but does not eliminate the perception of insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is a common practice among biotechnology executives to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to conduct orderly divestments while avoiding potential insider trading allegations.
• The scale of the sale (5,000 shares) is consistent with typical executive equity compensation management for mid-cap pharmaceutical companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was pre-planned and disclosed in accordance with SEC regulations.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Insider Trading, Form 4, Stock Options, Executive Compensation